FinnDiane LifeOne Study - Impact of Ageing on People With Type 1 Diabetes

NCT07289204 | Enrolling By Invitation

• 1 other identifier: HUS/4387/2023
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

Healthy aging refers to functional ability that enables well-being in older individuals. The focus thus shifts from chronological age to functional capacity and the individual's own experience of well-being. Type 1 diabetes is a chronic condition characterized by elevated blood glucose levels, which increases the risk of cardiovascular diseases and premature death. However, the life expectancy of individuals with type 1 diabetes has significantly improved due to advances in diabetes care. There is limited research on aging with type 1 diabetes, and this study is at the forefront of addressing this gap by examining aging-and especially healthy aging-in type 1 diabetes from multiple perspectives. The goals are to investigate how individuals with type 1 diabetes age and what their functional capacity is compared to individuals without insulin-treated diabetes. The other aim is to identify factors in midlife that predict healthy aging in people with type 1 diabetes.

Conditions

Diabetes Mellitus Type 1; Healthy Ageing

Keywords

Aging; Healthy Aging; Diabetes Mellitus, Type 1; Prospective Studies; Cohort Studies; Geriatric Assessment; Finland

Outcome Measures

Primary Outcomes (1)

• Healthy ageing in people with type 1 diabetes mellitus

  Key Characteristics and Clinical Implications of healthy aging in individuals with type 1 diabetes mellitus

  From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.

Secondary Outcomes (5)

• Physical capacity

  From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.

• Cognitive function

  From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.

• Psychological well-being

  From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.

• Vitality

  From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.

• Sensory function

  From initial enrollment in the FinnDiane Study until the LifeOne follow-up visit after three to five years.

Study Arms (2)

Type 1 diabetes

Participants of the Finnish Diabetic Nephropathy Study, age above 65 years.

Controls

Age above 65 years, no diabetes with insulin therapy

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants of the Finnish Diabetic Nephropathy (FinnDiane) Study living in the Helsinki capital area. Controls will be recruited from spouses to match for sex and socioeconomic factors.

You may qualify if:

• Participants of the Finnish Diabetic Nephropathy Study
• Type 1 diabetes
• With age above 65 years
• Informed consent provided

You may not qualify if:

• Age below 65 years

Sponsors & Collaborators

• Helsinki University Central Hospital: lead
• University of Helsinki: collaborator
• Folkhälsan Research Center: collaborator

Study Sites (1)

HUS Helsinki University Hospital

Helsinki, Finland

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate professor, Head physician, Helsinki University Hospital

Study Record Dates

• First Submitted: December 3, 2025
• First Posted: December 17, 2025
• Study Start: January 29, 2024
• Primary Completion (Estimated): December 31, 2030
• Study Completion (Estimated): December 31, 2030
• Last Updated: December 24, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

FI (1)